TCT Group

Targeted Cell Therapies (TCT) is a biotechnology company focused on developing a novel oral delivery platform for biologics and vaccines. The company utilizes proprietary yeast-derived Glucan Particles (GPs) to encapsulate therapeutic payloads, including proteins, peptides, and RNA, protecting them from degradation in the digestive tract. These particles are specifically designed to be taken up by M-cells in the gut and delivered to macrophages and dendritic cells, triggering targeted immune responses or systemic delivery. TCT's technology aims to transform the administration of complex therapeutics from injections to convenient oral formats. The company's current research focus includes treatments for inflammatory diseases and the development of oral vaccines.